CERO
Cero Therapeutics Holdings, Inc.
$0.01
0.00 (-8.33%)
At close · Jul 6
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$473,680
Shares
45,112,406
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.01
Open$0.01
Day$0.01–0.01
52W$0.01–9.57
Avg vol 30d1.1M
Short int5K · 0.0% float · 1.0d
Short vol39%
Last earningsOct 11, 2024
DataNov 2021–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−98% below
−
Price vs 50-day avg
−44% below
◦
RSI (14)
43 · neutral
+
MACD trend
positive
−
52-week position
0% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $0 › 200d $1 — 200d above 50d
+
Institutional flow
+22% holders QoQ · +3 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
0.01% of float · ▼ -84.7% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
11 holders — 13F breadth
Fundamentals
Excellent
+
EPS growth
+81% Y/Y
+
Balance sheet
net cash $96.9K
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−98% below
Bearish
Price vs 50-day avg
−44% below
Bearish
RSI (14)
43 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
0% · near low
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -84.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
11 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $10
vs 200-day avg -98%
vs 50-day avg -44%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CERO
this stock
Cero Therapeutics Holdings, Inc.
|
$473,680 | -83.6% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.87B | +9.0% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
11
- % held
- 0.3%
- Net QoQ
- -89.8K sh
- Top holder
- Parallel Advisors, LLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CERO | +0.0% | -21.4% | -78.0% | +0.0% | -83.6% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -3.1% | -20.7% | -86.2% | -0.6% | -93.8% |